Informasjon til prosjektledere knyttet til gjennomføring og administrasjon av pågående prosjekter er gitt i menyen nedenfor. Klikk på menyvalg for å gå videre til den aktuelle siden.
|
Sphenopalatine ganglion block in chronic migraine (MIBLOCK) |
Anders Mattias Linde |
St. Olavs hospital |
18.7 |
|
Innovative steroid treatment to reduce asthma development in first-time rhinovirus induced wheezing – INSTAR |
Henrik Døllner |
St. Olavs hospital |
20.0 |
|
Immunotherapy for Hematological Malignancies- A Path to Cure |
Henrik Hjorth-Hansen |
St. Olavs hospital |
5.7 |
|
Changing the specialist mental health care |
Gerd Kvale |
Helse Bergen |
20.0 |
|
Improved prediction of outcome by global strain and mechanical dispersion in patients with myocardial infarction, heart failure and primary prophylactic internal defibrillator |
Thor Edvardsen |
Oslo universitetssykehus |
17.8 |
|
BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function |
Dan Atar |
Oslo universitetssykehus |
15.0 |
|
Establishment of Molecular profiling for Individual clinical routine Treatment decisions in Early Breast Cancer (EMIT) |
Bjørn Naume |
Oslo universitetssykehus |
20.0 |
|
BACK-TO-BASIC – a study of the effect of infliximab on patients with long-term lower back pain and Modic changes |
John-Anker Zwart |
Oslo universitetssykehus |
17.9 |
Tildeling etter utlysning i 2016:
| Prosjekttittel | Prosjektleder | Koordinerende enhet | Mill. kr | Tenecteplase in wake-up ischaemic stroke trial – TWIST | Ellisiv B. Mathiesen | Universitetssykehuset Nord-Norge | 15.5 |
| A Phase 1b/2 clinical trial with Axl kinase inhibitor BGB324 in combination with Dabrafenib/Trametinib or Pembrolizumab in Metastatic Melanoma: Identification of predictive markers of response | Oddbjørn Straume | Helse Bergen | 17.6 |
| Randomized autologous hematopoietic stem cell transplantation vs. Alemtuzumab for patients with relapsing remitting Multiple sclerosis (RAM-MS) | Lars Bø | Helse Bergen | 20.0 |
| PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA-2) | Torbjørn Omland | Akershus universitetssykehus | 20.0 |
| The Nor-DRUM STUDY: assessing the effectiveness of tailoring infliximab treatment by therapeutic drug monitoring | Espen Andre Haavardsholm | Diakonhjemmet Sykehus AS | 12.4 |
| The ASAC-study: Acetylsalisylic Acid as Secondary Prevention in Colorectal Cancer | Bjørn Atle Bjørnbeth | Oslo universitetssykehus | 13.8 |
| The Norwegian Antibiotics for Pneumonia in Children (NAPiC) study | Håvard Ove Skjerven | Oslo universitetssykehus | 19.3 |
| Prosjekttittel | Prosjektleder | Koordinerende enhet | Mill. kr | Tenecteplase in wake-up ischaemic stroke trial – TWIST | Ellisiv B. Mathiesen | Universitetssykehuset Nord-Norge | 15.5 |
| A Phase 1b/2 clinical trial with Axl kinase inhibitor BGB324 in combination with Dabrafenib/Trametinib or Pembrolizumab in Metastatic Melanoma: Identification of predictive markers of response | Oddbjørn Straume | Helse Bergen | 17.6 |
| Randomized autologous hematopoietic stem cell transplantation vs. Alemtuzumab for patients with relapsing remitting Multiple sclerosis (RAM-MS) | Lars Bø | Helse Bergen | 20.0 |
| PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA-2) | Torbjørn Omland | Akershus universitetssykehus | 20.0 |
| The Nor-DRUM STUDY: assessing the effectiveness of tailoring infliximab treatment by therapeutic drug monitoring | Espen Andre Haavardsholm | Diakonhjemmet Sykehus AS | 12.4 |
| The ASAC-study: Acetylsalisylic Acid as Secondary Prevention in Colorectal Cancer | Bjørn Atle Bjørnbeth | Oslo universitetssykehus | 13.8 |
| The Norwegian Antibiotics for Pneumonia in Children (NAPiC) study | Håvard Ove Skjerven | Oslo universitetssykehus | 19.3 |